Study data shows that one-third of IDgenetix's medication recommendations are due to drug-drug interactions and lifestyle factors, helping guide neuropsychiatric drug selection for older adults in the 65+ patient cohort. The value of this additional information has been proven.The majority were taking five or more medications at the time of the test.
Friendswood, Texas, March 15, 2024–(BUSINESS WIRE)–Castle Biosciences (NASDAQ:CSTL), a company that improves health outcomes through innovative tests that guide patient care, today announced that IDgenetix Pharmacogenomics (PGx), a company that improves health outcomes through innovative tests that guide patient care, announced that ) released new data highlighting the value of testing. Patients aged 65 and older with mental illness are eligible. This data will be shared through a poster presentation at the 2024 American Academy of Geriatric Psychiatry (AAGP) Annual Meeting, March 15-18 in Atlanta.
“Pharmacogenomics is increasingly being used to identify genetic variations associated with drug response, but the potential of pharmacogenomics in older adults who take multiple drugs and are more likely to experience adverse drug events” “Sex is understudied,” says Dr. Robert Cook. ., senior vice president of research and development at Castle Biosciences. “In this study, one-third of the recommended medications had no drug-drug interactions provided in the IDgenetix report, even though all patients may have clinically significant genetic mutations. This is especially important because real-world evidence shows that polypharmacy is a condition in which older patients are more likely to take five or more prescription drugs. It occurs in more than half of the cases.1”
Poster title: Pharmacogenomic signature and IDgenetix-based drug management for older adults with depression and anxiety disorders
Presenting author: Raymond A. Lorenz, PharmD, BCPP, Castle Biosciences, Inc.
When: Saturday, March 16th, 5-7pm ET
Location: Hyatt Regency Atlanta Grand Ballroom, Hanover Hall, Embassy Hall Exhibition Level
IDgenetix is an advanced 3-in-1 PGx test that incorporates genetic information, drug interactions, and lifestyle factors to help clinicians choose the best medication for patients with depression, anxiety, and other neuropsychiatric disorders. Create reports to help you. In this study, a sample of IDgenetix reports for patients 65 and 65 years of age were analyzed by gender, age, attention-deficit/hyperactivity disorder, anxiety, bipolar disorder, depression, obsessive-compulsive personality disorder, pain, and anxiety. Diagnoses such as post-traumatic stress disorder and schizophrenia were analyzed. Older (n=737). The most common psychiatric diagnoses for which IDgenetix was ordered included depression and anxiety. Additionally, 58% of the patients in the study were taking five or more medications at the time of the study, with the average being seven.
All patients in the study had genetic polymorphisms in at least three of the 15 genes in the IDgenetix report that could influence drug selection. Drug-gene interactions account for 66% of all medication recommendations, while drug-drug interactions and lifestyle factors account for 34% (27% and 7%, respectively), making it difficult to customize treatment. The IDgenetix 3-in-1 test provides proven value. Guidance to help clinicians choose the best medication for their patients.
About IDgenetix
IDgenetix is a pharmacogenomic (PGx) test for depression, anxiety, and other mental health conditions that analyzes a patient's genetic makeup to make timely, evidence-based decisions about the best medication for each patient. It is designed to be possible. IDgenetix is designed to provide clinicians with critical genetic information to guide personalized treatment plans for patients, identifying the right drugs more efficiently than standard-of-care trials. Patients may be able to achieve a faster treatment response and increase their chances of remission. and error approach. IDgenetix provides drug-drug interactions and drug-gene interactions, published peer-reviewed randomizations that have demonstrated clinical utility over standard care when doctors use his IDgenetix before prescribing drugs. supported by controlled trials. IDgenetix currently has treatments for eight psychiatric disorders: major depressive disorder, schizophrenia, bipolar disorder, anxiety disorder, panic disorder, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention-deficit hyperactivity disorder. Reimbursed by Medicare.
About Castle Bioscience
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company that improves health through innovative tests that guide patient care. The company aims to transform disease management by putting people first: patients, clinicians, employees and investors.
Castle's current portfolio consists of tests for skin cancer, Barrett's esophagus, mental health conditions, and uveal melanoma. In addition, we are developing tests for other diseases with high clinical need, including tests in development to help select systemic therapies for patients with moderate to severe atopic dermatitis, psoriasis, and related diseases. We also have an active research and development program in testing. For more information, please visit www.CastleBiosciences.com, LinkedIn, Facebook, X And Instagram.
DecisionDx-Melanoma, DecisionDx-CMsequenceDecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME, and DecisionDx-UMsequence is a trademark of Castle Biosciences, Inc.
Forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Harbor” is applicable. section. These forward-looking statements include, but are not limited to, statements regarding: The potential for pharmacogenomics to influence medication recommendations for older adults. and the value of her IDgenetix 3-in-1 test, which provides customized guidance to help clinicians choose the best medication for their patients. Although the words “believe,” “could,” and similar expressions are intended to identify forward-looking statements, all forward-looking statements contain these identifying words. Not that there are. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events may differ materially from the plans, intentions and expectations disclosed in any forward-looking statements made by us. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, but not limited to: not. We do not endorse the results obtained in these studies, including the discussion of our testing in this press release. Application of our test in practice may not provide patients with the aforementioned benefits. and the risks described under the heading “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and other filings with the SEC. Forward-looking statements apply only as of the date on which they are made, and we undertake no obligation to update any forward-looking statements, except as required by law.
1. Wang X, Liu K, Shirai K, et al. Polypharmacy prevalence and trends among U.S. adults, 1999-2018. Glob Health Res Policy. 2023;8(25). https://doi.org/10.1186/s41256-023-00311-4
View source version on businesswire.com. https://www.businesswire.com/news/home/20240315064353/ja/
contact address
Investor contact information:
Camila Zucchero
czuckero@castlebiosciences.com
Media contact:
Alison Marshall
amarshall@castlebiosciences.com
